Phase 2 N=267 Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
HIV Infections
Primary: Mean Change in CD4+ T Lymphocyte Count — -21.8; 113.7; 110.4 cell/mm^3 — p=<.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 Endometrial Biopsy Instrument Comparison Study
Pain
Primary: Compare Pipelle and Explora Curette Groups With Respect to Patient Perception of Pain Associated With the Procedure as Rated by a 100mm Visual Analog Scale (VAS)…
Phase 2 N=43 Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
Prostate Cancer
Primary: The Number of Subjects Who Had Either an Increase or Decrease on Bone Mineral Density of the Lumbar Spine and Femoral Neck in Men Undergoing Androgen Deprivation Therapy…
Phase 4 N=82 Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
Intercritical Gout
Primary: Number of Gout Flares Per Participant From Day 1 to Week 16 — 1.1; 0.3 gout flares
Phase 3 N=200 Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
Salmonella Infections · Typhoid Fever · Bacterial Infections
Primary: Number of Participants With At Least a 4-Fold Rise in Vi Antibody Titers Following Vaccination With a Typhoid Vi Polysaccharide Vaccine — 173; 6; 5 Participants
Phase 1 N=6 AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled SSP-004184 — 251438.3 ng*hr/ml
Phase 2 N=36 Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
Acute Ischemic Stroke (AIS)
Primary: Number of Participants That Experienced Adverse Events — 0; 0; 0; 0 participants
N/A N=2,712 Effectiveness Comparison of Three Supplementary Foods in the Treatment of Moderate Acute Malnutrition
Malnutrition
Primary: Number of Participants With Nutritional Recovery — 763; 795; 807 participants
Phase 3 N=116 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Chronic Kidney Disease · Dialysis · Hyperphosphatemia
Primary: Number of Adverse Events (AE) — 109; 50; 63 participants
Phase 2 N=55 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer
Sarcoma
Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants
Phase 4 N=68 Infrapatellar Nerve Block for Post-operative Knee Arthroscopy Pain Control
Internal Derangement of Knee
Primary: Post op Pain Score — 5.5; 3.9 units on a scale
Phase 1 N=24 Effect of, OAT3, on the Renal Secretion of Cefotaxime
Focus Groups
Primary: Effect of OAT3 on Renal Secretion of Cefotaxime IV Based on Genotype — 84.8; 158 mL/min
Phase 4 N=60 A Study of Infliximab for Treatment Resistant Major Depression
Depression
Primary: Hamilton Depression Rating Scale 17 (HDRS-17) Scores — 24.1; 23.6; 20.8; 20.4 scores on a scale
Phase 3 N=21 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study
Cocaine Dependence
Primary: Cocaine Abstinence Based on Urine Toxicology Results — 1; 3 participants — p=<0.05
Phase 3 N=190 Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
Glaucoma · Ocular Hypertension
Primary: Mean Diurnal IOP Change From Baseline at Week 4 - Study Eye — -8.3; -6.6 mmHg